Diabetes Medication Fasting — FRCA Final MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Omit gliclazide and continue metformin as usual
Explanation lettering: E = shown as B · B = shown as C · C = shown as E
The correct answer is C. Gliclazide is a sulfonylurea that stimulates insulin secretion independently of food intake, so it risks hypoglycaemia during fasting; the CPOC/JBDS medication tables direct that sulfonylurea doses are omitted on the day of surgery for an afternoon list and not restarted until the patient is eating. Metformin taken once or twice daily is continued as normal because his eGFR exceeds 60 mL/min/1.73 m² and no iodinated contrast is planned, so lactic acidosis risk is not increased. Options A and B (full or half gliclazide dose) leave an avoidable hypoglycaemia risk. Option D needlessly omits metformin, worsening perioperative glycaemic control. Option E is excessive: a variable-rate intravenous insulin infusion is reserved for patients missing more than one meal or with persistently elevated glucose, whereas this man will miss a single meal and has a satisfactory glucose of 8.2 mmol/L.
Reference: Centre for Perioperative Care (CPOC), Guideline for Perioperative Care for People with Diabetes Mellitus Undergoing Elective and Emergency Surgery – Quick Reference Guide, medication adjustment table, 2021. https://www.mkuh.nhs.uk/wp-content/uploads/2022/07/CPOC-Guideline-for-Perioperative-Care-for-People-with-Diabetes-Mellitus-Undergoing-Elective-and-Emergency-Surgery-Quick-Reference-Guide.pdf